Echolucent implants

Patent metadata

Field	Value
Publication number	US-2020206365-A1
Application number	US-202016817291-A
Country	US
Kind code	A1
Filing date	Mar 12, 2020
Priority date	Dec 15, 2009
Publication date	Jul 2, 2020
Grant date	—

Abstract

Echolucent implantable materials may delivered to a selected placement site and biodegrade after a certain period of time. Applications include delivery of therapeutic agents to the placement site.

First claim

1 . A method for treating a patient comprising
delivering a pharmaceutically acceptable implant through an applicator into the patient at a selected placement site, the implant comprising a flowable, hydrolytically biodegradable polymer composition, an osmotic agent, and a therapeutic agent, wherein the flowable, hydrolytically biodegradable polymer composition comprises a collection of covalently-crosslinked hydrolytically biodegradable hydrogel particles, a hydrogel precursor composition that reacts to form covalent bonds at physiological conditions with the product being covalently-crosslinked hydrolytically biodegradable hydrogel particles, or a combination thereof, wherein the implant at the selected placement site is echolucent, and wherein the therapeutic agent is released from the hydrogel particles at the placement site.

2 . The method for treating a patient of claim 1 further comprising monitoring the delivering of the implant to the placement site with ultrasound.

3 . The method for treating a patient of claim 1 wherein the implant further comprises a pharmaceutically acceptable fluid and wherein the implant is delivered to the placement site as a slurry.

4 . The method for treating a patient of claim 1 wherein the applicator comprises a syringe, a catheter, a needle, or combinations thereof.

5 . The method for treating a patient of claim 1 wherein the applicator comprises a double barreled syringe.

6 . The method for treating a patient of claim 1 wherein the applicator comprises a syringe connected to a needle, and the delivering of the implant comprises injecting the implant through the needle into the placement site.

7 . The method for treating a patient of claim 1 wherein the hydrogel particles have an average diameter from about 10 microns to about 500 microns.

8 . The method for treating a patient of claim 1 wherein the hydrogel particles have an average diameter from about 125 microns to about 500 microns.

9 . The method for treating a patient of claim 1 wherein the implant further comprises an ultrasound contrast agent.

10 . The method for treating a patient of claim 1 wherein the implant further comprises a radiopaque agent.

11 . The method for treating a patient of claim 10 wherein the radiopaque agent is covalently attached to the polymer composition.

12 . The method for treating a patient of claim 1 wherein the therapeutic agent comprises a pain reliever, an anesthetic, a steroid, a chemotherapeutic agent, or combinations thereof.

13 . The method for treating a patient of claim 1 wherein the implant is adherent to a tissue at the placement site.

14 . The method for treating a patient of claim 1 wherein a volume of the implant after delivering at the placement site is no more than 50% more than a volume of the implant prior to delivering at the placement site and wherein the porosity is more than 30%.

15 . The method for treating a patient of claim 1 wherein the hydrogel particles have a time for degradation from about 7 days to about 180 days.

16 . The method for treating a patient of claim 1 wherein the hydrogel particles are hydrolytically biodegradable to produce degradation products that are absorbed into the circulatory system and cleared from the body via renal filtration.

17 . The method for treating a patient of claim 1 wherein the collection comprises dehydrated covalently-crosslinked hydrolytically biodegradable hydrogel particles.

18 . The method for treating a patient of claim 1 further comprising visualizing an interface of the implant and a tissue with ultrasound, X-ray, or a combination thereof.

19 . The method for treating a patient of claim 1 further comprising a step of mixing the polymer composition and the osmotic agent with the therapeutic agent to form the implant.

20 . The method for treating a patient of claim 1 wherein the osmotic agent comprises polyethylene glycol.

Assignees

• Incept Llc

Inventors

• Campbell Patrick
• Sawhney Amarpreet S

Classifications

• A61L27/50 Primary

  Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials} · CPC title

• A61K49/0442 Primary

  Polymeric X-ray contrast-enhancing agent comprising a halogenated group · CPC title

• A61L31/148

  Materials at least partially resorbable by the body · CPC title

• A61K51/1244

  microparticles or nanoparticles, e.g. polymeric nanoparticles · CPC title

• A61P15/00

  Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives · CPC title